Yassmin Moatasim

List of Publications by Citations

Source: https://exaly.com/author-pdf/8214689/yassmin-moatasim-publications-by-citations.pdf
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34 papers	685 citations	16 h-index	25 g-index
39 ext. papers	961 ext. citations	5.6 avg, IF	3.88 L-index

#	Paper	IF	Citations
34	Active surveillance for avian influenza virus, Egypt, 2010-2012. *Emerging Infectious Diseases*, **2014**, 20, 542-51	10.2	61
33	Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. *Emerging Microbes and Infections*, **2017**, 6, e1	18.9	49
32	FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. *Pharmaceuticals*, **2020**, 13,	5.2	47
31	Genetic and antigenic evolution of H9N2 avian influenza viruses circulating in Egypt between 2011 and 2013. *Archives of Virology*, **2014**, 159, 2861-76	2.6	43
30	Molecular characterization of avian influenza H5N1 virus in Egypt and the emergence of a novel endemic subclade. *Journal of General Virology*, **2014**, 95, 1444-1463	4.9	41
29	Synthesis and Anti-influenza Virus Activity of Novel bis(4H-chromene-3-carbonitrile) Derivatives. *Journal of Heterocyclic Chemistry*, **2017**, 54, 1854-1862	1.9	38
28	Genetic characterization of highly pathogenic avian influenza A H5N8 viruses isolated from wild birds in Egypt. *Journal of General Virology*, **2017**, 98, 1573-1586	4.9	37
27	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. *Emerging Microbes and Infections*, **2019**, 8, 103-108	18.9	36
26	Novel reassortant H9N2 viruses in pigeons and evidence for antigenic diversity of H9N2 viruses isolated from quails in Egypt. *Journal of General Virology*, **2017**, 98, 548-562	4.9	33
25	Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2. *Pathogens*, **2021**, 10,	4.5	33
24	Characterization of the recent outbreak of foot-and-mouth disease virus serotype SAT2 in Egypt. *Archives of Virology*, **2013**, 158, 619-27	2.6	30
23	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. *Viruses*, **2019**, 11,	6.2	29
22	Isolation and Characterization of a Distinct Influenza A Virus from Egyptian Bats. *Journal of Virology* , **2019**, 93,	6.6	27
21	Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. *Microbiology Resource Announcements*, **2020**, 9,	1.3	21
20	Delineating a potent antiviral activity of extract loaded nano-formulation against SARS-CoV-2: studies. *Journal of Drug Delivery Science and Technology*, **2021**, 66, 102845	4.5	21
19	Active surveillance and genetic evolution of avian influenza viruses in Egypt, 2016-2018. *Emerging Microbes and Infections*, **2019**, 8, 1370-1382	18.9	16
18	EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2. *PLoS ONE*, **2020**, 15, e0241739	3.7	15

17	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. *Vaccines*, **2021**, 9,	5.3	15
16	New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2. *Bioorganic Chemistry*, **2021**, 114, 105117	5.1	11
15	Single gene reassortment of highly pathogenic avian influenza A H5N1 in the low pathogenic H9N2 backbone and its impact on pathogenicity and infectivity of novel reassortant viruses. *Archives of Virology*, **2017**, 162, 2959-2969	2.6	10
14	Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19.. *AAPS PharmSciTech*, **2021**, 23, 44	3.9	10
13	Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. *Vaccine*, **2016**, 34, 218-224	4.1	9
12	Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics. *Antibiotics*, **2021**, 10,	4.9	9
11	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. *PLoS Pathogens*, **2021**, 17, e1009413	7.6	8
10	Structure- and Ligand-Based Studies towards the Repurposing of Marine Bioactive Compounds to Target SARS-CoV-2.. *Arabian Journal of Chemistry*, **2021**, 14, 103092	5.9	6
9	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. *Frontiers in Microbiology*, **2020**, 11, 596851	5.7	5
8	Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt. *Poultry Science*, **2019**, 98, 6289-6295	3.9	5
7	Comparative Virological and Pathogenic Characteristics of Avian Influenza H5N8 Viruses Detected in Wild Birds and Domestic Poultry in Egypt during the Winter of 2016/2017. *Viruses*, **2019**, 11,	6.2	4
6	Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. *PLoS ONE*, **2020**, 15, e0241471	3.7	4
5	3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2. *Bioorganic Chemistry*, **2021**, 114, 105131	5.1	4
4	Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. *Bioorganic Chemistry*, **2021**, 117, 105466	5.1	3
3	New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2. *ChemMedChem*, **2021**, 16, 3418-3427	3.7	2
2	Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil□NPs) against SARS-CoV-2 (in silico and in vitro study). *RSC Advances*, **2022**, 12, 15775-15786	3.7	2
1	Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies.. *RSC Advances*, **2021**, 11, 28876-28891	3.7	0